(RNAC) Cartesian Therapeutics - Ratings and Ratios
Cell Therapies, mRNA, CAR-T, Autoimmune Treatments, Biotechnology Products
RNAC EPS (Earnings per Share)
RNAC Revenue
Description: RNAC Cartesian Therapeutics
Cartesian Therapeutics Inc. (NASDAQ:RNAC) is a clinical-stage biotechnology company specializing in mRNA cell therapies for treating autoimmune diseases. The companys lead product, Descartes-08, is an autologous mRNA CAR-T therapy targeting B cell maturation antigen (BCMA), currently in Phase 2b clinical trials for various autoimmune diseases, including generalized myasthenia gravis and systemic lupus erythematosus.
From a business perspective, Cartesian Therapeutics has a promising pipeline with Descartes-08 and Descartes-15, another autologous anti-BCMA mRNA CAR-T therapy in development for treating autoimmune diseases and relapsed/refractory multiple myeloma. To evaluate the companys performance, key performance indicators (KPIs) such as research and development (R&D) expenses, cash burn rate, and clinical trial progression can be monitored. As of now, the companys market capitalization stands at $295.10M USD, indicating a relatively small-cap biotechnology firm.
Analyzing the companys valuation, the price-to-earnings (P/E) ratio is 2.13, suggesting a potentially undervalued stock. However, the forward P/E ratio is 25.45, indicating expected growth in earnings. The return on equity (RoE) of 118.52% is exceptionally high, possibly due to the companys focus on R&D and the potential for significant returns on investment in successful therapies. To further assess the companys prospects, investors can track milestones such as clinical trial results, regulatory approvals, and partnerships or collaborations that may impact the stocks performance.
From a trading perspective, the stocks current price is $13.77, with a 20-day simple moving average (SMA) of $10.73 and a 50-day SMA of $10.53, indicating a potential bullish trend. The 200-day SMA is $16.14, suggesting a longer-term bearish trend. The average true range (ATR) is 0.69, representing a 4.99% daily price movement, which can be considered relatively volatile. Investors can monitor these technical indicators to identify potential buy or sell signals.
Additional Sources for RNAC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
RNAC Stock Overview
| Market Cap in USD | 295m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2016-06-22 |
RNAC Stock Ratings
| Growth Rating | -81.4 |
| Fundamental | -9.02 |
| Dividend Rating | 0.0 |
| Rel. Strength | -23 |
| Analysts | 4.25 of 5 |
| Fair Price Momentum | 7.71 USD |
| Fair Price DCF | - |
RNAC Dividends
Currently no dividends paidRNAC Growth Ratios
| Growth Correlation 3m | 15.2% |
| Growth Correlation 12m | -51.1% |
| Growth Correlation 5y | -90.9% |
| CAGR 5y | -31.65% |
| CAGR/Max DD 5y | -0.34 |
| Sharpe Ratio 12m | -1.17 |
| Alpha | -62.17 |
| Beta | 2.607 |
| Volatility | 92.94% |
| Current Volume | 43.1k |
| Average Volume 20d | 52.3k |
| Stop Loss | 11.7 (-6.6%) |
As of July 19, 2025, the stock is trading at USD 12.53 with a total of 43,133 shares traded.
Over the past week, the price has changed by -7.46%, over one month by +27.99%, over three months by +19.33% and over the past year by -31.98%.
Neither. Based on ValueRay´s Fundamental Analyses, Cartesian Therapeutics is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -9.02 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RNAC is around 7.71 USD . This means that RNAC is currently overvalued and has a potential downside of -38.47%.
Cartesian Therapeutics has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy RNAC.
- Strong Buy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, RNAC Cartesian Therapeutics will be worth about 9.3 in July 2026. The stock is currently trading at 12.53. This means that the stock has a potential downside of -26.18%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 36.2 | 188.7% |
| Analysts Target Price | 36.2 | 188.7% |
| ValueRay Target Price | 9.3 | -26.2% |